Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)11,988.00
  • Today's Change-38.00 / -0.32%
  • Shares traded2.34m
  • 1 Year change1.22%
  • Beta0.3617
Data delayed at least 20 minutes, as of Apr 26 2024 15:04 BST.
More ▼

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

  • Revenue in GBP (TTM)38.12bn
  • Net income in GBP5.07bn
  • Incorporated1992
  • Employees89.90k
  • Location
    AstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
  • Phone+44 20 7304 5000Fax+44 20 7604 8151
  • Websitehttps://www.astrazeneca.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		AZN:LSE since
announced		Transaction
value
Fusion Pharmaceuticals IncAnnounced19 Mar 202419 Mar 2024Announced16.50%2.30bn
Amolyt Pharma SASAnnounced14 Mar 202414 Mar 2024Announced14.63%1.05bn
Gracell Biotechnologies IncDeal completed26 Dec 202326 Dec 2023Deal completed14.87%1.10bn
Icosavax IncDeal completed12 Dec 202312 Dec 2023Deal completed18.74%862.87m
Data delayed at least 20 minutes, as of Apr 26 2024 15:04 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Merck KGaA17.97bn2.42bn56.49bn62.91k56.49bn62.91k
GSK plc30.33bn4.93bn68.51bn70.21k68.51bn70.21k
Sanofi SA39.98bn3.89bn98.80bn87.99k98.80bn87.99k
Roche Holding AG51.41bn10.07bn158.38bn103.61k158.38bn103.61k
Novartis AG38.21bn7.29bn172.02bn76.06k172.02bn76.06k
AstraZeneca plc38.12bn5.07bn186.20bn89.90k186.20bn89.90k
Novo Nordisk A/S26.66bn9.61bn349.63bn63.37k349.63bn63.37k
Data as of Apr 26 2024. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

21.66%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202368.51m4.42%
Wellington Management Co. LLPas of 31 Dec 202365.12m4.20%
The Vanguard Group, Inc.as of 01 Apr 202455.70m3.59%
Norges Bank Investment Managementas of 01 Apr 202434.36m2.22%
BlackRock Fund Advisorsas of 01 Apr 202429.74m1.92%
BlackRock Advisors (UK) Ltd.as of 01 Apr 202421.99m1.42%
Legal & General Investment Management Ltd.as of 01 Apr 202415.37m0.99%
BlackRock Advisors LLCas of 01 Apr 202415.35m0.99%
SSgA Funds Management, Inc.as of 01 Apr 202415.23m0.98%
Fidelity Management & Research Co. LLCas of 01 Apr 202414.39m0.93%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.